Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Dry Eye > Panel takeaways: pearls of practice for dry eye disease
  • Dry Eye

Panel takeaways: pearls of practice for dry eye disease

Ophthalmology 360

In the final segment of a 5-part video series, Marjan Farid, MD, of the University of California, Irvine; Karolinne Rocha, MD, PhD, of the Medical University of South Carolina; Nathan Lighthizer, OD, of the Northeastern State University Oklahoma College of Optometry; and Cory Lappin, OD, the Dry Center of Ohio, give important practice takeaways for clinicians who treat patients with dry eye disease.

Watch from the beginning; go to part 1.

Marjan Farid, MD:

We’re looking forward to continuing to move this field of ocular surface disease forward. Any final thoughts?

Nathan Lighthizer, OD:

Just keep seeing those dry eye patients, keep tackling them. You’re not going to cure all of them. It’s okay to not have every patient completely asymptomatic. Follow them up, manage them, care for them, and you’re going to have happy dry eye patients.

Cory Lappin, OD:

To that point, we’ve all mentioned we have so many good options right now, and don’t suffer from analysis paralysis on this. Choose something and start somewhere. That’s the big thing right now, because it’s a great time, but some people are overwhelmed with all the options. Just choose one. The drum I keep beating is there’s only one wrong answer and it’s to do nothing. Just start somewhere, dive in, you’re going to learn more. Just if you see your dry patients, just choose something and run with it and they’re going to be grateful for it.

Karolinne Rocha, MD, PhD:

Remember that you can combine different therapies, because understanding that cascade is so important, because, again, we have a lot of great options that can help our patients.

Marjan Farid, MD:

Perfect. Thank you again for joining me and my amazing colleagues here today, and we hope this has been educational for you all.

Share

Related Content

  • The Interventional Glaucoma Project

Improving Patient Experience and Practice Workflow With an Interventional Glaucoma Approach

  • The Interventional Glaucoma Project

Data-Driven Focus on Interventional Glaucoma Care

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon